Schuler D
Department of Paediatrics, Semmelweis Medical University, Budapest, Hungary.
J Antimicrob Chemother. 1995 Jul;36 Suppl A:99-108. doi: 10.1093/jac/36.suppl_a.99.
In this multicentre, randomised study of 170 children hospitalised with bacterial infections, meropenem (10 to 20 mg/kg every 8 h) was found to be as effective and as well tolerated as cefotaxime (100 to 150 mg/kg/day), with or without amikacin or metronidazole. Most drug-related adverse events were mild and self-limiting. Neither regimen was associated with seizures. The overall incidence of clinically significant laboratory changes was similar in the two treatment groups. Satisfactory clinical responses were obtained in 94/96 (98%) patients treated with meropenem monotherapy and 43/46 (93%) children treated with cefotaxime regimens, while satisfactory bacteriological responses were obtained in 25/28 (89%) and 9/10 (90%) patients, respectively. Meropenem monotherapy appears to be a well-tolerated and effective drug for paediatric infections.
在这项针对170名因细菌感染住院的儿童的多中心随机研究中，发现美罗培南（每8小时10至20mg/kg）与头孢噻肟（100至150mg/kg/天）联合或不联合阿米卡星或甲硝唑相比，疗效相当且耐受性良好。大多数与药物相关的不良事件为轻度且可自行缓解。两种治疗方案均未引发癫痫。两个治疗组中具有临床意义的实验室指标变化的总体发生率相似。接受美罗培南单药治疗的94/96（98%）名患者和接受头孢噻肟治疗方案的43/46（93%）名儿童获得了满意的临床反应，而分别有25/28（89%）和9/10（90%）名患者获得了满意的细菌学反应。美罗培南单药治疗似乎是一种耐受性良好且有效的儿科感染用药。
